Jennifer Schlegel

MERTK receptor tyrosine kinase is a therapeutic target in melanoma

Jennifer Schlegel, Maria J. Sambade, Susan Sather et al. · Journal of Clinical Investigation · 2013 · 144 citations · Full text

Medicine, Cancer Biology, Oncology +17

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

Alisa B. Lee‐Sherick, K M Eisenman, Susan Sather et al. · Oncogene · 2013 · 106 citations · Full text

Medicine, Hematology, Oncology +17

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia <i>In Vitro</i> and <i>In Vivo</i>

Sandra Christoph, Deborah DeRyckere, Jennifer Schlegel et al. · Molecular Cancer Therapeutics · 2013 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Solution Characterization of the Extracellular Region of CD147 and Its Interaction with Its Enzyme Ligand Cyclophilin A

Jennifer Schlegel, Jasmina S. Redzic, Christopher C. Porter et al. · Journal of Molecular Biology · 2009 · 73 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +6

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia

Luis Brandão, Amanda Winges, Sandra Christoph et al. · Blood Cancer Journal · 2013 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17